SCHEMBL633918

SCHEMBL633918

O=Cc1cc[n+]([O-])c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.39
MEN1 O00255 5/20 0.39
LMNA P02545 4/20 0.39
BLM P54132 2/20 0.39
THRB P10828 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
IMPDH2 P12268 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 3/20 0.38
CHAT P28329 1/20 0.38
MITF O75030 1/20 0.38
CYP2A6 P11509 2/20 0.36
HTT P42858 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
NPSR1 Q6W5P4 4/20 0.35
PKM P14618 2/20 0.35
MAPK1 P28482 2/20 0.35
RAD52 P43351 2/20 0.35
KDM4E B2RXH2 3/20 0.33
PABPC1 P11940 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL876926 0.77 CHAT (0.62) KMT2AMEN1LMNABLMTHRB
SCHEMBL29357465 0.77 CHAT (0.62) KMT2AMEN1LMNABLMTHRB
SCHEMBL7155648 0.74 MITF (0.37) LMNAMAPTMITFHTTRAB9A
SCHEMBL4609887 0.73 CHAT (0.53) KMT2AMEN1LMNABLMALDH1A1
SCHEMBL6827498 0.71 MAPT (0.38) LMNAMAPTMITFHTTNPSR1
SCHEMBL6554349 0.70 CHAT (0.49) KMT2AMEN1LMNABLMALDH1A1
SCHEMBL5784218 0.69 MAPT (0.53) KMT2ALMNAALDH1A1MAPTMITF
SCHEMBL450730 0.69 CHKA (0.46) KMT2AMEN1LMNABLMTDP1
SCHEMBL2795974 0.69 CYP2A6 (0.44) KMT2ALMNAMAPTMITFCYP2A6
SCHEMBL1770982 0.69 MAPT (0.39) KMT2ALMNABLMTHRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7524859-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2009-04-28 US disclosed
CN-100471841-C (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2009-03-25 CN disclosed
CN-101087782-A (2-carboxamido)(3-amino) thiophene compounds OSI PHARM INC (US) 2007-12-12 CN disclosed
EP-1590328-A4 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2007-09-19 EP disclosed
EP-1807419-A1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed
US-20060247275-A1 (2-carboxamido)(3-amino)thiophene compounds CREW ANDREW P 2006-11-02 US disclosed
US-7101893-B2 (2-Carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2006-09-05 US disclosed
WO-2006047574-A1 (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2006-05-04 WO disclosed
CN-1723200-A (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2006-01-18 CN disclosed
EP-1590328-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2005-11-02 EP disclosed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US disclosed
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds CREW ANDREW P (US) 2005-09-01 US disclosed
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds OSI PHARMACEUTICALS, INC. 2005-07-14 US disclosed
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-04-28 US disclosed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US disclosed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed
CN-1511151-A 3-quinoline-2-(1H)-ylideneindolin-2-one derivatives ֮����ҩ��ʽ���� 2004-07-07 CN disclosed
EP-1396490-A1 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds ABL1, NAT1, KRAS KMT2A 785/4885MEN1 892/4885LMNA 4752/4885
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative KDR, FLT4, FLT1 KMT2A 2370/4885MEN1 2955/4885LMNA 4317/4885
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds AADAC, PAM, TPMT KMT2A 121/4885MEN1 1646/4885LMNA 4345/4885
US-20060247275-A1 (2-carboxamido)(3-amino)thiophene compounds PCNA, MKI67, MYC KMT2A 1228/4885MEN1 1387/4885LMNA 2104/4885
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds PCNA, MKI67, TPMT KMT2A 827/4885MEN1 717/4885LMNA 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.